523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents

BACKGROUND: Nirmatrelvir/ritonavir (n/r) is a currently 1 of 2 oral medications FDA-approved for treatment of COVID-19 in patients ≥ 12 years of age AND ≥ 40 kg. To date, dosing recommendations for adolescents are extrapolated primarily from adult studies. We conducted a retrospective study at a lar...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kiriam Escobar, Lee, Philip J, Anosike, Brenda I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677984/
http://dx.doi.org/10.1093/ofid/ofad500.592

Ejemplares similares

Ejemplares similares